Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Advicenne's Enterprise Value is €43.22 Mil.
Advicenne's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €1.83 Mil. Therefore, Advicenne's EV-to-FCF for today is 23.63.
The historical rank and industry rank for Advicenne's EV-to-FCF or its related term are showing as below:
STU:3MM'
s EV-to-FCF Range Over the Past 10 Years
Min: -47.73 Med: -5.5 Max: 2136.77
Current: 23.85
During the past 12 years, the highest EV-to-FCF of Advicenne was 2136.77. The lowest was -47.73. And the median was -5.50.
STU:3MM's EV-to-FCF is ranked worse than 58.98% of 334
companies
in the Biotechnology industry
Industry Median: 15.69
vs STU:3MM: 23.85
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Advicenne's share price for today is €1.686.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Advicenne's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.717.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Advicenne EV-to-FCF Related Terms
Advicenne EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Advicenne's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Advicenne's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advicenne EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Advicenne's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Advicenne's EV-to-FCF falls into.
Advicenne's current Enterprise Value is €43.22 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Advicenne's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €1.83 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advicenne (STU:3MM) has a EV-to-FCF of 23.63 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Advicenne and its competitors. According to the industry distribution chart, Advicenne ranks #197 out of 334 companies in the Biotechnology industry, placing it in the top 59%.
Is Advicenne's EV-to-FCF too high?
Advicenne's current EV-to-FCF is 23.63. The Biotechnology industry median EV-to-FCF is 15.69. Advicenne's value of 23.63 is 50.6% above this industry median. Based on the distribution chart, Advicenne ranks #197 out of 334 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Advicenne has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advicenne's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Advicenne ranks #197 out of 334 companies for EV-to-FCF. This places Advicenne in the lower half of its industry. The industry median EV-to-FCF is 15.69. Advicenne's value of 23.63 is 50.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.69, based on 334 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Advicenne's current EV-to-FCF of 23.63 is 50.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Advicenne and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advicenne's current EV-to-FCF is 23.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advicenne stock overvalued right now?
Based on GuruFocus' analysis, Advicenne (STU:3MM) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.01, compared to a current price of €1.69 — trading 16.1% below its estimated fair value. The current EV-to-FCF is 23.63 and 50.6% above the Biotechnology industry median of 15.69. Advicenne's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Advicenne (STU:3MM), the current EV-to-FCF is 23.63 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Advicenne (STU:3MM) Overvalued in 2026?
Based on GuruFocus' analysis, Advicenne stock appears to be undervalued.
The current stock price of €1.69 is trading 16.1% below its estimated GF Value™ of €2.01.
GuruFocus considers Advicenne to be Modestly Undervalued.
Key valuation signals for STU:3MM:
EV-to-FCF: 23.63
GF Value™: €2.01 vs. price of €1.69 (16.1% below fair value)
Industry Position: 50.6% above the Biotechnology median (#197 of 334)
No single metric tells the full story. See the STU:3MM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Advicenne SA is a late-stage biopharmaceutical company. The company is engaged in the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. Its goal is to improve the lives of patients from early childhood through adulthood.
53GF Score
Get the complete analysis for STU:3MM
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:3MM has been successfully added to your 
